Table 3

Unadjusted and adjusted clinical and safety outcomes in patients with proximal M2 segment MCA occlusion, single vessel M2 segment middle cerebral artery (MCA) occlusions and dominant M2 segment MCA occlusions

OutcomeEndovascular treatment group, % (n/N)Control group, % (n/N)UnadjustedAdjusted
Odds ratio (95% CI)P valueOdds ratio (95% CI)P value
Proximal M2 segment MCA (n=116)
 mRS 0–257.1% (36/63)37.7% (20/53)2.24 (1.04 to 4.81)0.042.68 (1.13 to 6.37)0.027
 mRS at 90 daysN/AN/A1.96 (1.01 to 3.8)0.0481.95 (0.98 to 3.87)0.059
 mRS 0–136.5% (23/63)18.9% (10/53)3.07 (0.95 to 9.9)0.0633.03 (0.81 to 11.24)0.101
 NIHSS 0–228.6% (18/63)5.9% (3/51)6.4 (1.77 to 23.21)0.0056.09 (1.55 to 23.99)0.011
 sICH0.0% (0/63)7.5% (4/53)00.041
 Death11.1% (7/63)7.5% (4/53)1.53 (0.42 to 5.55)0.5181.58 (0.38 to 6.63)0.532
Dominant M2 segment MCA (n=73)
 mRS 0–261.5% (24/39)44.1% (15/34)1.91 (0.72 to 5.1)0.1984.08 (1.08 to 15.48)0.042
 mRS at 90 daysN/AN/A1.96 (0.84 to 4.6)0.1252.76 (1.07 to 7.11)0.039
 mRS 0–135.9% (14/39)17.6% (6/34)3.04 (0.6 to 15.31)0.1823.69 (0.8 to 16.91)0.098
 NIHSS 0–233.3% (13/39)3.0% (1/33)16 (1.96 to 130.5)0.01640.42 (3.3 to 495.48)0.005
 sICH0.0% (0/39)5.7% (2/35)00.22
 Death5.1% (2/39)5.9% (2/34)0.86 (0.12 to 6.5)0.88820.22 (0.02 to 2.35)0.215
Single vessel M2 segment MCA (n=123)
 mRS 0–258.5% (38/65)37.9% (22/58)2.34 (1.12 to 4.91)0.0252.73 (1.19 to 6.27)0.019
 mRS at 90 daysN/AN/A2.03 (1.07 to 3.86)0.0331.92 (0.99 to 3.73)0.054
 mRS 0–138.5% (25/65)19.0% (11/58)3.2 (1.06 to 9.71)0.0423.24 (0.93 to 11.29)0.067
 NIHSS 0–227.7% (18/65)7.1% (4/56)4.98 (1.57 to 15.77)0.0074.98 (1.43 to 17.34)0.01
 sICH0.0% (0/65)6.8% (4/59)00.048
 Death10.8% (7/65)6.9% (4/58)1.62 (0.45 to 5.85)0.4641.69 (0.4 to 7.08)0.477
  • mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Score; sICH, symptomatic intracerebral hemorrhage.